Yujia Wang

Follow

Generating author description...

All published works

Action	Title	Year	Authors
+	Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References	2021	Fuyu Song Xin Xiao Zheng Yujia Wang Shein‐Chung Chow Hongqiang Sun

Common Coauthors

Coauthor	Papers Together
Shein‐Chung Chow	1
Hongqiang Sun	1
Xin Xiao Zheng	1
Fuyu Song	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies.	1994	Dieter Hauschke W V Steinijans E Diletti Robert Schall H. G. Luus M. Elze H Blume	1
+	A note on sample size determination for bioequivalence studies with high-order crossover designs.	1997	Keh-Wei Chen Shein‐Chung Chow Gang Li	1
+	Sample size determination for bioequivalence assessment using a multiplicative model	1992	Dieter Hauschke V W Steinijans E Diletti Martin D. Burke	1
+ PDF Chat	The N-Of-1 Clinical Trial: The Ultimate Strategy For Individualizing Medicine?	2011	Elizabeth O. Lillie Bradley Patay Joel Diamant Brian F. Issell Eric J. Topol Nicholas J. Schork	1
+ PDF Chat	Bioavailability and bioequivalence in drug development	2014	Shein‐Chung Chow	1
+	Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study	2016	Kun He Huanyu Chen Thomas Gwise Sandra J. Casak Steven J. Lemery Patricia Keegan Richard Pazdur Rajeshwari Sridhara	1
+	On hybrid parallel–crossover designs for assessing drug interchangeability of biosimilar products	2016	Shein‐Chung Chow Fuyu Song Can Cui	1
+ PDF Chat	Biosimilars: Key regulatory considerations and similarity assessment tools	2017	Carol F. Kirchhoff Xiao‐Zhuo Michelle Wang Hugh D. Conlon Scott Anderson Anne Ryan Arindam Bose	1
+	Expanding the Role of N-of-1 Trials in the Precision Medicine Era: Action Priorities and Practical Considerations	2018	Karina W. Davidson Ying Kuen Cheung Thomas McGinn Y. Claire Wang	1
+	Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?	2019	Chien-Lung Tu Yi-Lin Wang Teh‐Min Hu Li-Feng Hsu	1
+	Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies	2019	Michael J. Grayling Adrian Mander James Wason	1
+	Simultaneous confidence interval methods for analytical similarity assessment	2019	Jiayin Zheng Donglei Yin Mengdie Yuan Shein‐Chung Chow	1